Eron Joseph J
University of North Carolina, Chapel Hill, NC, USA.
Top HIV Med. 2009 Dec;17(5):146-50.
There is a continuing need for new antiretroviral drugs and formulations and updated strategies for using new and established drugs. Strategies being investigated for expanding initial treatment options include use of rilpivirine, raltegravir, or maraviroc as an alternative to efavirenz, use of pharmacokinetics enhancers without anti-HIV activity as an alternative to ritonavir as a boosting agent, and use of regimens sparing nucleoside analogue reverse transcriptase inhibitors, including ritonavir-boosted (/r) lopinavir plus raltegravir; darunavir/r plus raltegravir; vicriviroc plus atazanavir/r; and unboosted atazanavir plus raltegravir. For patients receiving fully suppressive regimens, strategies such as switching from lopinavir/r to raltegravir and from enfuvirtide to raltegravir have been examined. In highly treatment-experienced patients, use of 3 new active drugs has been found to be successful in suppressing virus. This article summarizes a presentation made by Joseph J. Eron, Jr, MD, at the International AIDS Society-USA continuing medical education program in Chicago in May 2009. The original presentation is available as a Webcast at www.iasusa.org.
持续需要新型抗逆转录病毒药物和制剂以及使用新药和现有药物的更新策略。正在研究的扩大初始治疗选择的策略包括使用利匹韦林、拉替拉韦或马拉维罗替代依非韦伦，使用无抗HIV活性的药代动力学增强剂替代利托那韦作为增效剂，以及使用节省核苷类逆转录酶抑制剂的方案，包括利托那韦增效的洛匹那韦（/r）加拉替拉韦；达芦那韦/r加拉替拉韦；维克立韦罗加阿扎那韦/r；以及未增效的阿扎那韦加拉替拉韦。对于接受完全抑制方案的患者，已研究了从洛匹那韦/r转换为拉替拉韦以及从恩夫韦肽转换为拉替拉韦等策略。在治疗经验丰富的患者中，使用3种新型活性药物已被证明能成功抑制病毒。本文总结了医学博士小约瑟夫·J·埃伦于2009年5月在芝加哥举行的美国国际艾滋病学会继续医学教育项目上的一次演讲。原始演讲可在www.iasusa.org上作为网络直播获取。
